FOURIER: How Low Should LDL Go?

What should primary care docs know about LDL-lowering effects of the PCSK9 inhibitor evolocumab? A leading cardiologist discusses results of the FOURIER trial.

http://www.medscape.com/viewarticle/878456

Source: Medscape Internal Medicine Podcast - April 14, 2017 Category: Internal Medicine Authors: Medscape Source Type: podcasts

More News: Cardiology | Heart | Internal Medicine | Podcasts | Primary Care